The cost of Ralyeso (ralimetinib) is not publicly disclosed by the manufacturer [1]. Pricing for prescription medications can vary widely based on factors such as insurance coverage, pharmacy, and geographic location [2].
How much does Medicare cover for Ralyeso?
Medicare coverage for Ralyeso depends on whether it is administered in a doctor's office or an outpatient hospital setting [3]. For drugs administered in a doctor's office, Medicare Part B generally covers them if they are medically necessary and approved by the FDA [3]. For drugs administered in an outpatient hospital setting, Medicare Part B also covers them, but there may be different copayments or coinsurance [3]. Patients are advised to contact their Medicare provider to understand their specific coverage and potential out-of-pocket costs for Ralyeso [3].
Are there financial assistance programs for Ralyeso?
Financial assistance programs may be available to help eligible patients afford Ralyeso. These programs can include manufacturer-sponsored patient assistance programs, non-profit foundations, and co-pay assistance cards [4]. Patients should inquire with their healthcare provider or the Ralyeso manufacturer to explore available options [4].
What is the typical cost of similar cancer medications?
The cost of cancer medications can vary significantly. For instance, some targeted cancer therapies can range from thousands to tens of thousands of dollars per month, depending on the drug, dosage, and treatment duration [5]. Factors like the complexity of the drug, its efficacy, and the research and development investment contribute to pricing [5].
How does insurance affect the price of Ralyeso?
Insurance plays a crucial role in determining a patient's out-of-pocket cost for Ralyeso. Prescription drug plans have formularies that list covered medications and their associated cost-sharing tiers [6]. The level of coverage, deductibles, copayments, and coinsurance will influence the final price a patient pays [6]. Patients with high-deductible plans or those whose insurance does not cover Ralyeso may face higher costs [6].
Who manufactures Ralyeso?
Ralyeso (ralimetinib) is manufactured by Sanofi [1].
What is Ralyeso used to treat?
Ralyeso is indicated for the treatment of adults with advanced or metastatic HER2-negative, hormone receptor-positive breast cancer in combination with fulvestrant, after prior therapy [1].
---
1. Sanofi. (n.d.). Ralyeso™ (ralimetinib). Retrieved from https://www.sanofi.com/
2. U.S. Food and Drug Administration. (n.d.). Drug Development Process. Retrieved from https://www.fda.gov/
3. Centers for Medicare & Medicaid Services. (n.d.). Medicare & You. Retrieved from https://www.medicare.gov/
4. Patient Advocate Foundation. (n.d.). Co-Pay Programs. Retrieved from https://www.patientadvocate.org/
5. National Cancer Institute. (n.d.). Costs of Cancer Care. Retrieved from https://www.cancer.gov/
6. Kaiser Family Foundation. (n.d.). Prescription Drug Coverage. Retrieved from https://www.kff.org/